trending Market Intelligence /marketintelligence/en/news-insights/trending/ZZZaYj15_-6GLTJCB6A_mw2 content esgSubNav
In This List

Former Regulus Therapeutics exec joins AmpliPhi Biosciences as CEO

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Former Regulus Therapeutics exec joins AmpliPhi Biosciences as CEO

AmpliPhi Biosciences Corp. appointed Paul Grint to the position of CEO, effective May 31.

Grint previously worked as president and CEO of biopharmaceutical company Regulus Therapeutics Inc.

M. Scott Salka has resigned as CEO and director of AmpliPhi and will serve as a consultant to the company during a transition period.